Morphosys Reports Decreased Losses in Q2

1 Mins read

By Andrea Figueras

Morphosys, the German biopharmaceutical company, announced improved financial performance in the second quarter of the year. Despite a decline in revenue, lower costs helped narrow net and operating losses.

Strong Improvement in Financials

Morphosys reported a significant decrease in net loss for Q2, reducing it to 74 million euros ($81.2 million) compared to the previous year’s loss of EUR235 million. The company also saw a reduction in operating loss, with figures dropping from EUR55.1 million to EUR50.5 million.

Revenue Decline Offset by Cost Reductions

Although revenue dipped by 10% to EUR53.2 million, Morphosys successfully mitigated the impact through cost-cutting measures. The quarterly sales of Monjuvi, the company’s main product which treats lymphoma, remained stable at EUR21.7 million.

Positive Outlook for Monjuvi

Morphosys maintains a positive outlook for Monjuvi, anticipating net product sales in the U.S. to range between $80 million and $95 million for the year. The company expects a gross margin of 75% to 80% for Monjuvi and estimates research-and-development expenses to be between EUR290 million and EUR315 million.

Related posts

Unexpected Stock Market Rally

2 Mins read
Despite mixed expectations and original justifications falling apart, the stock market rally continues to soar, reaching new highs in various sectors. Let’s…

Analyst Sees Opportunity in DraftKings Stock

2 Mins read
A roughly 10% pullback in DraftKings Inc.’s stock following last week’s earnings report has caught the attention of analysts. Barclays’ Brandt Montour…

Bloomin' Brands Inc. Fourth-Quarter Report

1 Mins read
Despite a lower fourth-quarter profit, Bloomin’ Brands Inc. (BLMN) managed to exceed analyst estimates with its adjusted earnings thanks to a strong…

Leave a Reply

Your email address will not be published. Required fields are marked *

7 + 3 =